Document Detail


Influence of anti-Helicobacter triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora.
MedLine Citation:
PMID:  11552917     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Proton pump inhibitor-based therapy including two antibiotics is the treatment of choice for Helicobacter pylori infection. Oral antibiotic treatment can lead to intestinal overgrowth of potentially pathogenic bacteria. AIM: To investigate the intestinal microflora before and at different times after H. pylori treatment with omeprazole, clarithromycin and metronidazole. METHODS: Bacterial growth in faecal samples from 51 patients infected with H. pylori was determined qualitatively and quantitatively. During the same period of time, stool samples from 27 H. pylori-negative controls were taken and investigated at the same intervals. RESULTS: The microflora of H. pylori-infected patients was different from that in H. pylori negative controls. It was characterized by a high concentration of lactobacilli, mainly Lactobacillus acidophilus. Immediately after therapy there was an increased colonization with yeasts, while the growth of lactobacilli and other species was inhibited. Clostridium difficile was cultured from three cases, but without clinical manifestations of pseudomembranous colitis. After 4 weeks of therapy, the microflora returned to normal and was not different from that of the H. pylori-negative control group. CONCLUSIONS: In H. pylori-positive patients the intestinal flora is characterized by an increase in growth of acid-tolerant L. acidophilus. Eradication therapy exerts only a short-term influence on intestinal flora, whereas in the long term, the intestinal microflora is restored to a pattern similar to that of the control group.
Authors:
A Bühling; D Radun; W A Müller; P Malfertheiner
Related Documents :
15785037 - Gastric perception thresholds are low and sensory neuropeptide levels high in helicobac...
10458177 - Mooren ulcer in south india: serology and clinical risk factors.
9468247 - Anti-helicobacter pylori specific antibody immunohistochemistry improves the diagnostic...
9438317 - Gastric b-cell clonal expansion and helicobacter pylori infection in patients with auto...
21546847 - Limited risk of drug resistance after discontinuation of antiretroviral prophylaxis for...
21278627 - Did national hiv prevention programs contribute to hiv decline in eastern zimbabwe? evi...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  15     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2001 Sep 
Date Detail:
Created Date:  2001-09-12     Completed Date:  2001-10-25     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1445-52     Citation Subset:  IM    
Affiliation:
State Institute of Hygiene Saxony-Anhalt, Magdeburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Bacterial Agents / administration & dosage,  therapeutic use*
Anti-Ulcer Agents / administration & dosage,  therapeutic use*
Case-Control Studies
Clarithromycin / administration & dosage,  therapeutic use*
Drug Therapy, Combination
Feces / microbiology
Female
Helicobacter Infections / drug therapy*
Helicobacter pylori*
Humans
Lactobacillus acidophilus / isolation & purification
Male
Metronidazole / administration & dosage,  therapeutic use*
Omeprazole / administration & dosage,  therapeutic use*
Proton Pumps / antagonists & inhibitors
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Anti-Ulcer Agents; 0/Proton Pumps; 443-48-1/Metronidazole; 73590-58-6/Omeprazole; 81103-11-9/Clarithromycin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Octreotide increases the proportions of arachidonic acid-rich phospholipids in gall-bladder bile.
Next Document:  Outcomes of Helicobacter pylori treatment in community practice and impact of therapeutic effectiven...